Clinical Trials Directory

Trials / Completed

CompletedNCT05939518

Fluid Therapy and Glycocalyx Shedding During Moderate Surgery

The Contribution of Liberal Fluid Therapy to Glycocalyx Shedding, Interstitial Edema and Fluid Accumulation During Moderate Surgery

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
51 (actual)
Sponsor
Hadassah Medical Organization · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Goal-directed fluid therapy is one of the most accepted strategies in intraoperative fluid therapy, although potential fluid overload is a possible drawback. Fluid overload has recently been shown to cause damage to the glycocalyx and to increase extravasation of fluids into the interstitial space. This study aims to determine whether liberal fluid administration during moderate surgery results in impairment to the endothelial glycocalyx and causes edema. Participants will be randomized to receive either a liberal or restrictive fluid protocol with vasopressor support. The investigators will measure interstitial edema by clinical signs, pulmonary congestion by ultrasound, and extracellular water by bioimpedance. Impairment of glycocalyx will be estimated by measuring blood levels of shedding markers. In addition, wound healing and early postoperative outcome will be estimated by POMS.

Conditions

Interventions

TypeNameDescription
OTHERLactated Ringer's Fluid Bolus Response to Low Urinary OutputDuring the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.
OTHERPost-Anesthesia Care Unit Lactated Ringer's Fluid Management ProtocolDuring their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.

Timeline

Start date
2020-05-13
Primary completion
2023-08-03
Completion
2023-08-03
First posted
2023-07-11
Last updated
2024-12-18

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT05939518. Inclusion in this directory is not an endorsement.